Voyager Therapeutics (STU:VT6) Short Interest


STU:VT6 Voyager Therapeutics Inc STU:VT6
55 GF Score
Price €3.22
GF Value €1.52
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Voyager Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:VT6 vs CRBU, OBIO, WHWK: Short Interest Comparison

For the Biotechnology subindustry, Voyager Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Short Interest falls into.


STU:VT6
55GF Score
Voyager Therapeutics Inc STU:VT6
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Voyager Therapeutics (STU:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €3.22 is trading 112.1% above its estimated GF Value™ of €1.52. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:VT6:

  • Short Interest:
  • GF Value™: €1.52 vs. price of €3.22 (112.1% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the STU:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
55GF Score

Get the complete analysis for STU:VT6

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.22
Price
€1.52
GF Value